Biotech week ahead, Feb. 15

 Biotech stocks advanced in the week ended Feb. 12, thanks to broader market strength and company-specific catalysts. Small and mid-cap earnings, multiple conference presentations, data readouts and a slew of IPOs were all part of the week's news flow.

Regeneron Pharmaceuticals Inc REGN 1% received two FDA approvals during the week. Immunotherapy Libtayo, which the company co-developed with Sanofi SA SNY 0.27%, got a label expansion as a treatment option for basal cell carcinoma. Regeneron also received the nod for its Evkeeza, as an adjunctive treatment option for ultra-rare cholesterol disease.

Ocugen Inc OCGN 6.46% and Kalvista Pharmaceuticals Inc KALV 5.24% were among the best performing stocks of the week. The former moved on momentum gathered on the back of a U.S. COVID-19 vaccine deal with Bharat Biotech and the news of an offering priced at a premium. Kalvista gained on a positive data readout.

Conferences

BIO CEO & Investor Digital Conference: Feb. 16-18

PDUFA Dates

The FDA is set to rule on G1 Therapeutics Inc's GTHX 5.22% new drug application for trilaciclib as a treatment option for mitigating the impact of chemotherapy in small-cell lung cancer. The PDUFA date by which the verdict has to be issued is Monday, Feb. 15.

Earnings

Monday

Medpace Holdings Inc MEDP 0.54%

Tuesday

Zoetis Inc ZTS 1.05% (before the market open)
EXACT Sciences Corporation EXAS 5.68% (after the market close)

Wednesday

Royalty Pharma plc RPRX 1.42% (before the market open)
Ironwood Pharmaceuticals, Inc. IRWD 1.28% (before the market open)
Blueprint Medicines Corp BPMC 3.33% (before the market open)
10X Genomics Inc TXG 3.55% (after the close)
Invitae Corp NVTA 1.55% (after the close)
Globus Medical Inc GMED 1.26% (after the close)
Shockwave Medical Inc SWAV 2.21% (after the close)
Veracyte Inc VCYT 1.08% (after the close)
Viking Therapeutics Inc VKTX 3.67% (after the close)

Thursday

West Pharmaceutical Services Inc. WST 1.14% (before the market open)
Syneos Health Inc SYNH 0.69% (before the market open)
Avanos Medical Inc AVNS 1.61% (before the market open)
Integra Lifesciences Holdings Corp IART 0.6% (before the market open)
Emergent Biosolutions Inc EBS 1.27% (after the close)
Quidel Corporation QDEL 0.64% (after the close)
Opko Health Inc. OPK 1.63% (after the close)

https://www.benzinga.com/general/biotech/21/02/19644551/the-week-ahead-in-biotech-fda-decision-on-g1-therapeutics-earnings-in-the-mix-for-light-calendar-